A phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan

International Archives of Allergy and Immunology

Volumn 169, Issue 3, 2016, Pages 135-145

  Park, Hae Sim ^a   Kim, Mi Kyeong ^b   Imai, Nobuyuki ^c   Nakanishi, Tsutomu ^c   Adachi, Mitsuru ^d   Ohta, Ken ^e   Tohda, Yuji ^f  

^a Ajou University Medical CentSuwon   (South Korea)

^b Chungbuk National University Hospital   (South Korea)

^c KYOWA HAKKO KOGYO CO LTD   (Japan)

^d INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^e TOKYO NATIONAL HOSPITAL   (Japan)

^f KINKI UNIVERSITY   (Japan)

Author keywords

Anti interleukin 5 receptor; Asthma exacerbation; Benralizumab; Eosinophilic asthma; Eosinophils

Indexed keywords

BENRALIZUMAB; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; LONG ACTING DRUG; PLACEBO; PREDNISONE; ANTIASTHMATIC AGENT; BIOLOGICAL MARKER; INTERLEUKIN 5 RECEPTOR; MONOCLONAL ANTIBODY;

ACUTE SINUSITIS; ADULT; AGED; ALLERGIC RHINITIS; ARTHRALGIA; ARTICLE; ASTHMA; BACKACHE; BRONCHITIS; CHRONIC SINUSITIS; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAST ASIAN; ECZEMA; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC ASTHMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HUMAN; HYPERTENSION; INJECTION SITE ERYTHEMA; INSOMNIA; INTESTINE POLYP; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OROPHARYNX PAIN; OTITIS MEDIA; PERENNIAL RHINITIS; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SOUTH KOREA; STOMATITIS; SUBCUTANEOUS IMMUNOTHERAPY; SYSTEMIC THERAPY; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; CYTOLOGY; DISEASE COURSE; DRUG EFFECTS; EOSINOPHIL; IMMUNOLOGY; LEUKOCYTE COUNT; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOLOGY; SPUTUM; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; BIOMARKERS; DISEASE PROGRESSION; EOSINOPHILS; FEMALE; HUMANS; JAPAN; LEUKOCYTE COUNT; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-5; REPUBLIC OF KOREA; RESPIRATORY FUNCTION TESTS; SPUTUM; TREATMENT OUTCOME;

EID: 84964267747     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000444799     Document Type: Article

References (27)

1. Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention, updated 2012. http://www.ginasthma. org.
2. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353: 364-369.
3. Masoli M, Fabian D, Holts S, Beasley R; Global Initiative for Asthma (GINA) Program: The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469-478.
4. Hambly N, Nair P. Monoclonal antibodies for the treatment of refractory asthma. Curr Opin Pulm Med 2014; 20: 87-94.
5. Japanese Society of Allergology: Asthma Prevention and Management Guideline 2012 (in Japanese). Tokyo, Kyowa Kikaku, 2012.
6. Di Franco A, Bartoli ML, Carnevali S, Cianchetti S, Bacci E, Dente FL, Giannini D, Taccola M, Vagaggini B, Paggiaro PL. Analysis of sputum cell counts during spontaneous moderate exacerbations of asthma in comparison to the stable phase. J Asthma 2003; 40: 155-162.
7. Scott KA, Wardlaw AJ. Eosinophilic airway disorders. Semin Respir Crit Care Med 2006; 27: 128-133.
8. Zhang JY, Wenzel SE. Tissue and BAL based biomarkers in asthma. Immunol Allergy Clin North Am 2007; 27: 623-632.
9. Holgate ST. Mechanism of asthma and implications for its prevention and treatment: a personal journey. Allergy Asthma Immunol Res 2013; 5: 343-349.
10. Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2012; 42: 712-737.
11. Uhm TG, Kim BS, Chung IY. Eosinophil development, regulation of eosinophil-specific genes, and role of eosinophil in the pathogenesis of asthma. Allergy Asthma Immunol Res 2012; 4: 68-79.
12. Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, Wilkins HJ, Henkel T, Nair P; Res-5-0010 Study Group: Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125-1132.
13. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.
14. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993.
15. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-659.
16. Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall'acqua WW, Stephens GL, Erjefalt JS, Bjermer L, Humbles AA, Gossage D, Wu H, Kiener PA, Spitalny GL, Mackay CR, Molfino NA, Coyle AJ. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010; 125: 1344-1353.e2.
17. Takatsu K, Dickason RR, Huston DP. Interleukin 5; in Bondy C, LeRoith C (eds): Growth Factors and Cytokines in Health and Disease. Cytokines, Part A. Amsterdam, Elsevier, 1997.
18. Toba K, Koike T, Shibata A, Hashimoto S, Takahashi M, Masuko M, Azegami T, Takahashi H, Aizawa Y. Novel technique for the direct flow cytofluorometric analysis of human basophils in unseparated blood and bone marrow, and the characterization of phenotype and peroxidase of human basophils. Cytometry 1999; 35: 249-259.
19. Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, Coyle AJ, Koike M, Spitalny GL, Kiener PA, Geba GP, Molfino NA. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010; 125: 1237-1244.e2.
20. Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, Busse WW, Wenzel S, Wu Y, Datta V, Kolbeck R, Molfino NA. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132: 1086-1096.e5.
21. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, Khatry DB, van der Merwe R, Kolbeck R, Molfino NA, Raible DG. Benralizumab, an anti-interleukin 5 receptor a monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014; 2: 879-890.
22. Pizzichini E, Pizzichini MM, Efthimiadis A, Hargreave FE, Dolovich J. Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J 1996; 9: 1174-1180.
23. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14: 902-907.
24. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99: 553-558.
25. Juniper EF, Bousquet J, Abetz L, Bateman ED; GOAL Committee: Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006; 100: 616-621.
26. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. Am J Respir Crit Care Med 2000; 161: 309-329.
27. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, de Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE; American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations: An official American Thoracic Society/ European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.